The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 09, 2025
Filed:
Oct. 23, 2019
Applicant:
Myelopro Diagnostics and Research Gmbh, Vienna, AT;
Inventors:
Oleh Zagrijtschuk, Vienna, AT;
Ruochen Jia, Vienna, AT;
Assignee:
MYELOPRO DIAGNOSTICS AND RESEARCH GmbH, Vienna, AT;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 498/04 (2006.01); C07D 311/94 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 491/052 (2006.01); C07D 491/147 (2006.01); C07D 491/22 (2006.01); C07D 493/04 (2006.01);
U.S. Cl.
CPC ...
C07D 498/04 (2013.01); C07D 311/94 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 491/052 (2013.01); C07D 491/147 (2013.01); C07D 491/22 (2013.01); C07D 493/04 (2013.01);
Abstract
The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such compounds as well as to their use in treating diseases or conditions caused by or associated with a mutation of CALR, in particular myeloid malignancies, such as myeloproliferative neoplasms or myelodysplasia syndrome. The present invention also relates to screening assays allowing the identification of such compounds.